Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing oncology therapies for solid tumors. The company's pipeline centers on two main strategies: developing CR-001 (SKB118), a PD-1 x VEGF bispecific antibody designed to target immune checkpoints and vascular endothelial growth factor, and building a portfolio of antibody drug conjugates (ADCs). Key pipeline assets include CR-002, a PD-L1-directed ADC delivering a topoisomerase toxin, and CR-003 (SKB105), an integrin beta-6-directed ADC. The company initiated a global Phase 1/2 trial for CR-001 in early 2026 and anticipates starting monotherapy trials for CR-002 and CR-003 later in the year. Crescent Biopharma has established a partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to acquire exclusive rights to CR-003 outside of Greater China and granted Kelun exclusive rights to CR-001 in that region. The company also maintains an ADC Discovery and Option Agreement with Paragon Therapeutics, Inc. Formerly known as GlycoMimetics, Inc., the company was incorporated in 2003 and completed a reverse recapitalization transaction in 2025.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage crescentbiopharma.com
Sector Healthcare IR page investors.crescentbiopharma.com
Tags
oncology, bispecific antibodies, antibody drug conjugates, solid tumors, immune checkpoint inhibitors, clinical-stage, pd-1, vegf, pd-l1, topoisomerase inhibitors, CR-001, SKB118, CR-002, CR-003, SKB105, ASCEND trial, Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Paragon Therapeutics Inc., GlycoMimetics Inc.
Press page —

Metrics

Valuation  
Market cap $ 557.063M
Market cap (USD) $ 557.063M
P/E -3.13
PEG —
P/BV 2.03
P/S 51.37
P/OCF -7.30
P/FCF -7.69
Dividend yield —
Turnover / mcap —
Returns  
ROE -75.8%
ROI —
ROIC —
Profit margin -1,419.6%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025
Revenue 10.844M
Net profit -153.942M
Free cash flow -72.451M

Figure FY 2025
Share price 11.86
P/FCF -4.51

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — — 0.00 18M
Lease liabilities (USD) — — 4.3M 3.62M 2.82M 1.92M 918,555 808,402 66,844 1.64M
Cash and deposits (USD) 40M 124M 210M 158M 137M 90.3M 47.9M 41.8M 10.7M 213M
Right-of-use assets (USD) — — 3.6M 3.01M 2.33M 1.58M 751,174 767,828 0.00 1.47M
Cash flow detail
Operating cash flow (USD) -29.7M -29.8M -43.3M -52M -39.2M -57.5M -46.5M -34.9M -31.1M -71.5M
Purchases of property, plant and equipment (USD) -704,202 -294,107 -125,618 -144,928 -68,507 -14,943 -84,191 -21,394 -9,972 -919,000
Purchases of intangible assets (USD) — — — — — — — — — -72M
Change in receivables (cash effect) (USD) — — — — — — — — — -18M
Change in payables (cash effect) (USD) 1M 1.06M 16,488 -1.23M 654,279 17,676 -1.14M -102,076 -538,811 —
Income taxes paid (cash effect) (USD) — — — — — — — — — 0.00
Share-based compensation (USD) 2.96M 3.76M 4.59M 6.22M 6.9M 6.09M 3.86M 3.52M 4.7M 13.3M
Operating cash flow before change in receivables (USD) — — — — — — — — — -53.5M
Free cash flow (OCF - PPE - intangibles) (USD) -30.4M -30.1M -43.5M -52.1M -39.3M -57.5M -46.5M -34.9M -31.1M -144M
Income detail
Research and development expense (USD) 23.3M 24.1M 40.1M 47M 44.9M 47.5M 28.4M 20.1M 14.3M 138M
↳ 5y CAGR +20.6% +27.9% +19.2% +12.4% +15.3% +3.3% -12.9% -21.2% +25.2%
Total comprehensive income (USD) — — — — — — — — — -154M
Comprehensive income to owners (USD) — — — — — — — — — -154M
Reported Mar 1, 2017 Mar 6, 2018 May 2, 2019 Feb 28, 2020 Mar 2, 2021 Mar 3, 2022 Mar 29, 2023 Mar 27, 2024 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027

Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in China led by partner, Kelun-Biotech, with initial data in NSCLC expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned; partnership achieved 9 IND clearances this year

First patient dosed in global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC

On track for multiple clinical data readouts in 2027 and more than 2,000 patients dosed across the portfolio by mid-year

Waltham, Mass., November 12, 2026 – Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2026 and recent business highlights.

November 3, 2026

PDF Version

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 11,775 shares of the Company’s ordinary shares to one non-executive employee as an equity inducement award under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 2, 2026 and were material to the employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $12.91, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on November 2, 2026. The options granted to the employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the options shall vest and become exercisable monthly thereafter, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedInand X.

November 2, 2026

PDF Version

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

  • **Guggenheim 3rd Annual Healthcare Innovation Conference,**fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.

  • **Stifel 2026 Healthcare Conference,**fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.

  • Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.

A live webcast of each presentation will be available in the Investors section of the Company's website athttps://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedInand X.

Prompts

Crescent Biopharma, Inc. (ticker CBIO), listed in United States.

Company History

Date Change Detail
Mar 17, 2025 Renamed GLYCOMIMETICS INC → CRESCENT BIOPHARMA, INC.
— Different company GYRE THERAPEUTICS, INC. (CIK 1124105) is a different company that has used this ticker. Its filings are not shown here.
— Former tickers GLYC

ETFs Holding Crescent Biopharma, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 25 $ 450.00 Jun 30, 2026
DFSU 0.00% 2,673 $ 38.411K Nov 12, 2026